Vaxcyte, Inc. (PCVX)
NASDAQ · Healthcare
Vaxcyte, Inc. EBITDA 2020–2025
Vaxcyte, Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Vaxcyte, Inc. ebitda for the quarter ending March 31, 2026 was -340.0 M, a 93.27% increase year-over-year.
- Vaxcyte, Inc. ebitda for the twelve months ending March 31, 2026 was -1.1 B.
- Vaxcyte, Inc. annual ebitda for 2025 was -898.8 M, a 100.59% increase from 2024.
- Vaxcyte, Inc. annual ebitda for 2024 was -448.1 M, a 42.16% increase from 2023.
- Vaxcyte, Inc. annual ebitda for 2023 was -315.2 M, a 66.09% increase from 2022.
- Vaxcyte, Inc. annual ebitda for 2022 was -189.8 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Vaxcyte, Inc. EBITDA — FAQ
Vaxcyte, Inc. (PCVX) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see PCVX's ebitda history?
The chart and table above show Vaxcyte, Inc.'s ebitda by year and by quarter, including the growth rate.